The effects of mycophenolate mofetil and mycophenolate sodium on kidney transplant recipients at the University Hospital for Nephrology and Urology in Minia, Egypt

In conclusion, there was no statistically significant difference in the safety or effectiveness of MMF and MPS. Compared to maintenance MMF dosages, MPS doses were greater. It is possible that immunosuppression will be improved with these greater dosages. There was no discernible difference in the two regimens' efficacies, nevertheless, according to our research. When deciding on a myco-phenolic acid derivative, cost should be a major factor.

Introduction

Peptic ulcer disease is a frequent side effect of KTx that may cause serious health problems or even death. ⁽¹⁾ To treat or prevent difficulties over the long term, proton pump inhibitors (PPIs) are added ^{( 2)}. The impact of the interaction on the active blood levels of the medicine is debatable, however drug-drug interactions (DDIs) can occur when MMF or EC-MPS are used with PPIs. Hence, patients treated with mycophenolate in conjunction with proton pump inhibitors should be closely monitored, according to DDI checkers supplied by drug databases. ⁽³⁾.

Researchers have looked at how PPIs interact with other drugs, but they haven't compared their findings on how this affects long-term clinical outcomes such graft loss, graft survival, or death. Few participants and short study durations characterize the present state of pharmacological impact comparison research ^(4.

Aim of the work

In order to investigate the relative merits of tacrolimus-based MMF and MPS in patients undergoing renal transplantation

Patients and Methods

The participants in this case-control research had 300 Minia University Hospital's outpatient clinic will be used to recruit patients.

Two categories of subjects are formed:

Group I: Fifty-five patients undergoing a renal transplant on MPS

Group II: Fifty-five patients undergoing renal transplantation on MFF

We compared between 2 groups:

1- The rate of rejection in both groups

2- GIT symptoms in both groups

Here is what every patient may expect:

1- Complete patient history

2- Reason for carrying a donor kidney

3-Gastrointestinal issues after kidney transplant

4- Regular laboratory tests, such as complete blood count (CBC), uric acid, renal function, urine analysis, calcium, and phosphorus

Statistical Analysis

Descriptive analysis was used to assess the

features and results of the patients. For nominal categorical values expressed as percentages, the chi-square test was used, while for non-parametric continuous variables, the Mann-Whitney U test was employed, with median and interquartile range being the corresponding descriptions (IQR).

Discussion

Here are the findings:

The two groups vary significantly in terms of body mass index (BMI) and dosage (twice), with a p value of less than 0.001.

For all other demographic variables, there was no statistically significant difference between the two sets of data.

The p value (<0.001) indicates that there is a statistically significant difference between the two groups in terms of S.Cr and a/c ratio.

Other laboratory measurements did not show a statistically significant difference between the two groups.

Other clinical data factors did not show a statistically significant difference between the two groups.

The most common side effects of mycophenolic acid derivatives are gastroint-estinal problems (particularly diarrhoea) and leukopenia.

Recent research on heart transplant recipients found that gastrointestinal side effects were just as common in patients on MMF (61.6 percent) as they were in those taking MPS (69.2 percent) after 12 months. Among kidney transplant recipients, gastrointestinal side symptoms were reported by 33.3% of MMF patients and 32.4% of MPS patients. Similar gastrointestinal side effects are produced by intravenous and oral administration of MMF. Thus, it has been proposed that the onset of gastrointestinal adverse effects associated with mycophenolic acid derivatives does not occur during gastrointestinal consumption but rather starts thereafter. ^(5-9)

So far, only the MMF to MPS conversion has been carried out among mycophenolic acid derivatives. It is likely that the development of MPS suggested it as a medication with less gastrointestinal side effects, which is why it is used in this fashion in clinical practice—a one-way conversion. This claim was borne up by preliminary research. ⁽¹⁰⁾

As previously stated, further research has shown that individuals whose treatment plans were changed from MMF to MPS do better clinically. Though only a tiny percentage of well-designed trials with control groups have shown conclusive evidence of the efficacy of numerous one-way conversion trials in medicine. There was no discernible difference in effectiveness between the two groups. Prior research on this topic has yielded contradictory conclusions. ^(11-15)